Whereas therapeutics targeting these markers have been developed and have benefited a large population of patients, triple-negative breast cancers usually represent a more aggressive pathological type with a poor prognosis, suggesting the critical involvement of pro-survival and pro-metastasis signaling pathways other than ER/PR and HER2 pathways [34]-[36]. Here, PGR is linked to triple-negative breast carcinoma.